These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16051943)

  • 21. Target-based agents in neoadjuvant treatment of liver metastases from colorectal cancer: secret weapons in anti-cancer war?
    Marra M; Giudice A; Arra C; Vitale G; Castiglioni S; Nasti G; Lombardi A; Ottaiano A; Facchini G; Iaffaioli RV; Abbruzzese A; Caraglia M
    Cancer Biol Ther; 2009 Sep; 8(18):1709-18. PubMed ID: 19729997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients.
    Millet G; Truant S; Leteurtre E; Hebbar M; Zerbib P; Huet G; Boleslawski E; Pruvot FR
    Ann Surg; 2012 Nov; 256(5):755-61; discussion 761-2. PubMed ID: 23095619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.
    Aussilhou B; Dokmak S; Faivre S; Paradis V; Vilgrain V; Belghiti J
    Ann Surg Oncol; 2009 Jun; 16(6):1553-9. PubMed ID: 19363584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study.
    Mahfud M; Breitenstein S; El-Badry AM; Puhan M; Rickenbacher A; Samaras P; Pessaux P; Lopez-Ben S; Jaeck D; Figueras J; Alain-Clavien P
    World J Surg; 2010 Jan; 34(1):92-100. PubMed ID: 19838754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Recurrent liver sigmoid cancer responding remarkably to neoadjuvant chemotherapy using bevacizumab/XELOX: report of a case].
    Uehara M; Sakamoto K; Konishi S; Hamasu S; Nishitai R; Manaka D
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1541-3. PubMed ID: 21918359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Timing of the liver resection for patients with synchronous metastases: practical and outcome considerations.
    Mansour J; Fong Y
    Ann Surg Oncol; 2007 Sep; 14(9):2435-6. PubMed ID: 17562115
    [No Abstract]   [Full Text] [Related]  

  • 27. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases.
    Wicherts DA; de Haas RJ; Sebagh M; Saenz Corrales E; Gorden DL; Lévi F; Paule B; Azoulay D; Castaing D; Adam R
    Br J Surg; 2011 Mar; 98(3):399-407. PubMed ID: 21254017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A case with liver resection of metastasis from rectal cancer after FOLFOX4+bevacizumab treatment].
    Kojima T; Matsui T; Uemura T; Fujimitsu Y; Kure N; Kojima H
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1761-3. PubMed ID: 18931584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases.
    Covey AM; Brown KT; Jarnagin WR; Brody LA; Schwartz L; Tuorto S; Sofocleous CT; D'Angelica M; Getrajdman GI; DeMatteo R; Kemeny NE; Fong Y
    Ann Surg; 2008 Mar; 247(3):451-5. PubMed ID: 18376189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation.
    Starlinger P; Alidzanovic L; Schauer D; Maier T; Nemeth C; Perisanidis B; Tamandl D; Gruenberger B; Gruenberger T; Brostjan C
    Br J Cancer; 2012 Sep; 107(6):961-6. PubMed ID: 22850548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].
    Otsuka S; Inagaki M; Nishie M; Hamano R; Tokunaga N; Takahashi K; Tsunemitsu Y; Miyoshi K; Iwakawa K; Takahashi M; Iwagak H
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2166-8. PubMed ID: 20037358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
    Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study.
    Spiliotis J; Zoras O
    World J Surg; 2011 May; 35(5):1153-4. PubMed ID: 21184075
    [No Abstract]   [Full Text] [Related]  

  • 34. The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection.
    Cheon EC; Small W; Strouch MJ; Krantz SB; Rademaker A; Mulcahy MF; Benson AB; Bentrem DJ; Talamonti MS
    J Surg Oncol; 2010 Oct; 102(5):539-42. PubMed ID: 20812264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients.
    Ganapathi AM; Westmoreland T; Tyler D; Mantyh CR
    J Am Coll Surg; 2012 Apr; 214(4):582-8; discussion 588-90. PubMed ID: 22321523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recurrent disease four years after surgery and adjuvant chemotherapy.
    Pozzo C; Barone C
    Cancer Treat Rev; 2008; 34 Suppl 2():S8-11. PubMed ID: 19101406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Curing patients with liver metastases from colorectal cancer.
    Drug Ther Bull; 2011 Apr; 49(4):42-5; quiz i-ii. PubMed ID: 21467575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant chemotherapy used for colorectal liver and lung metastasis resections.
    Redondo Capafons S; Planas Giner A; Garriga Biosca R; Pla Poblador R
    Farm Hosp; 2011; 35(5):255.e1-5. PubMed ID: 21439881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab, bleeding, thrombosis, and warfarin.
    Kilickap S; Abali H; Celik I
    J Clin Oncol; 2003 Sep; 21(18):3542; author reply 3543. PubMed ID: 12972536
    [No Abstract]   [Full Text] [Related]  

  • 40. Bevacizumab beyond progression: does this make sense?
    Ellis LM; Haller DG
    J Clin Oncol; 2008 Nov; 26(33):5313-5. PubMed ID: 18854567
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.